Deep remission in Crohn's disease: is it the end of the placebo effect?
Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Henri Poincaré University, Vandœuvre-lès-Nancy, France.
Laurent
L
Peyrin-Biroulet
D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015990:Placebo Effect; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab